|
|
(HealthNewsDigest.com) – ATLANTA–Researchers at Winship Cancer Institute, Emory University are testing whether a combination of two anti-cancer agents can stop the growth of a hard-to-treat form of breast cancer.
“Triple-negative” breast cancers get their name because they lack three biological markers that make other breast cancers vulnerable to drugs such as tamoxifen or Herceptin.
A well-tested class of drugs called EGFR inhibitors has not been effective against this type of breast cancer by themselves, but doctors think that adding a second class of drugs, mTOR inhibitors, can block cancer cells’ escape route. After showing that this approach — lapatinib plus rapamycin — can stop growth in triple-negative cell lines, Winship researchers are testing it in a clinical trial.
Read more @ http://bit.ly/triplenegativedrugcombo
Check us out via social media @ http://bit.ly/emoryhealthscisocial
# # #
Subscribe to our FREE Ezine and receive current Health News, be eligible for discounted products/services and coupons related to your Health. We publish 24/7.
www.HealthNewsDigest.com
For advertising/promotion, email: [email protected] Or call toll free: 877- 634-9180